Showing 1 to 10 of 1,979
| Title | Reference number | Reference number sort | Published | Published date sort | Last updated | Last updated sort |
|---|---|---|---|---|---|---|
| COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders | Reference number:NG167 | NG00167 | Published:03 April 2020 | 20200403 | Last updated:02 July 2020 | 20200702 |
| Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer | Reference number:TA638 | TA00638 | Published:01 July 2020 | 20200701 | Last updated:01 July 2020 | 20200701 |
| Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer | Reference number:TA639 | TA00639 | Published:01 July 2020 | 20200701 | Last updated:01 July 2020 | 20200701 |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) | Reference number:TA634 | TA00634 | Published:30 June 2020 | 20200630 | Last updated:30 June 2020 | 20200630 |
| Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) | Reference number:TA635 | TA00635 | Published:30 June 2020 | 20200630 | Last updated:30 June 2020 | 20200630 |
| Eculizumab for treating refractory myasthenia gravis (terminated appraisal) | Reference number:TA636 | TA00636 | Published:30 June 2020 | 20200630 | Last updated:30 June 2020 | 20200630 |
| Ranibizumab for treating diabetic retinopathy (terminated appraisal) | Reference number:TA637 | TA00637 | Published:30 June 2020 | 20200630 | Last updated:30 June 2020 | 20200630 |
| COVID-19 rapid evidence summary: vitamin D for COVID-19 | Reference number:ES28 | ES00028 | Published:29 June 2020 | 20200629 | Last updated:29 June 2020 | 20200629 |
| Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention | Reference number:IPG673 | IPG00673 | Published:24 June 2020 | 20200624 | Last updated:24 June 2020 | 20200624 |
| Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia | Reference number:MTG49 | MTG00049 | Published:24 June 2020 | 20200624 | Last updated:24 June 2020 | 20200624 |